Nordic Issuing

Ongoing case

Curasight A/S

Back to all cases

Curasight A/S

16 Sep - 7 Oct 2021Warrent exercise

Curasight is a Danish biotech company pioneering in the development of intelligent cancer imaging and more gentle and efficient treatment of cancer, using nuclear medicine. Curasight’s novel uPAR Theranostics technology is based on more than 10 years of research at Rigshospitalet in Copenhagen by Professor Andreas Kjær and his group. The technology minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with the precise uTRACE® diagnostics. Curasight‘s imaging technology is now tested in a broad pipeline of investigator-initiated phase II clinical trials.

Read more at the company's website

The offer in summary

Exercise period: September 16th, 2021 - October 7th, 2021

Trading in warrants: Until October 5th, 2021

Subsription price: DKK 17.20

Payment date: October 7th, 2021

About the warrant: One (1) TO 1 warrent will be traded to one (1) stock.

Please notice! If you are a Danish investor with your warrants held in Nordnet, your subscription and payment shall be made through the bank.



  Teaser (Eng) Teaser (DK)


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.